Kite, a Gilead Company , today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous ...
Axon Neuroscience’s active tau immunotherapy, AADvac1, has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Phase 2 Alzheimer’s disease clinical trial, while ...
Evaluating quality of life (QOL) in patients with idiopathic pulmonary fibrosis (IPF) goes beyond lung function numbers. It also shows how treatments affect daily well-being and guides funding, ...
The word “sudden” signals that the timeline has shifted in an important way, often prompting more urgent questions and ...
Neurodegenerative diseases (NDs) are among the most urgent global health challenges, affecting millions worldwide and placing a growing burden on healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results